FACULTY
Anna Bar, MD
Associate Professor of Dermatology
Co-director of Mohs Micrographic Surgery
Oregon Health & Science University (OHSU)
Portland, OR
Justin Leitenberger, MD
Assistant Professor of Dermatology
Co-director of Mohs Micrographic Surgery
Oregon Health & Science University (OHSU)
Portland, OR
PROGRAM OVERVIEW
This case-based online enduring will focus on treatment and management of patients with advanced/metastatic basal cell skin cancer.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Mohs surgeons, onco-dermatologists, medical oncologists, dermatologists and other healthcare practitioners who care for patients with advanced/metastatic basal cell skin cancer.
LEARNING OBJECTIVES
On completing of the program, attendees should be able to:
- Discuss the pathogenic drivers of BCC including cellular signaling pathways and immune dysfunction
- Review the utility of Mohs micrographic surgery in the evaluation and therapeutic intervention in BCC
- Describe systemic therapeutic approaches in the treatment of locally advanced and metastatic BCC
- Summarize the clinical trial data for emerging immunotherapy agents for advanced or metastatic basal cell skin cancer
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with advanced/metastatic basal cell skin cancer.
Credits: 1.0 ANCC Contact Hour.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Anna Bar, MD receives consulting fees from Castle and Regeneron Pharmaceuticals. She received research funding to her institution from Castle, Pelle Pharm, and Polynoma.
Justin Leitenberger, MD has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Chris Drury, Medical Director for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: June 3, 2021
EXPIRATION DATE: June 3, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
ENDURING LEARNER NOTIFICATION
Med Learning Group
A 3D View: Addressing the Most Common Cancer: The Pathology, Epidemiology, and Treatment Options of Advanced and Metastatic BCC
Date of CE Release: June 3, 2021
Date of CE Expiration: June 3, 2022
Online
Acknowledgement of Financial Commercial Support
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-108-H04-P / JA4008163-9999-21-108-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Objectives – After Attending This Program You Should Be Able To
- Discuss the pathogenic drivers of BCC including cellular signaling pathways and immune dysfunction.
- Review the utility of Mohs micrographic surgery in the evaluation and therapeutic intervention in BCC.
- Describe systemic therapeutic approaches in the treatment of locally advanced and metastatic BCC.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5).
All individuals in a position to control the content of CE are listed below:
| Name | Relationship: Commercial Interest |
|---|---|
| Anna Bar | Consulting Fees: Regeneron Pharmaceuticals; Research Funding: Castle, Mavis, Pelle Pharm |
| Felecia Beachum | NA |
| Chris Drury | NA |
| Matthew Frese | NA |
| Christina Gallo | NA |
| Brianna Hanson | NA |
| Justin Leitenberger | NA |
| Scott McGee-Plys | NA |
| Lauren Welch | NA |
How to Get Your Certificate
- Go to http://mlg.cmecertificateonline.com
- Click on “ENDURING ACTIVITY- A 3D View: Addressing the Most Common Cancer: The Pathology, Epidemiology, and Treatment Options of Advanced and Metastatic BCC” link.
- Complete the post-test, click the provided link to go to the online evaluation site.
- Evaluate the meeting, click the provided link to open your credit certificate.
- Print/save all pages of your certificate for your records.
Questions?
Email [email protected]
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
